ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 03/07/2014

Grantor: CDER IND/IDE Number: 064402 Serial Number:

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis (AIR-BX2)

This study has been completed.

Sponsor:	Gilead Sciences
Collaborators:	
Information provided by (Responsible Party):	Gilead Sciences
ClinicalTrials.gov Identifier:	NCT01314716

Purpose

The AIR-BX2 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3 times a day. Each course was followed by a 28-day off-drug period. Following the two blinded courses, all participants received a 28-day course of open-label AZLI then were followed for an additional 56 days.

Condition	Intervention	Phase
Bronchiectasis	Drug: AZLI Drug: Placebo	Phase 3

Study Type: Interventional
Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Investigator), Randomized, Efficacy Study
Official Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/ Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2)

Further study details as provided by Gilead Sciences:

Primary Outcome Measure:

- Change in QOL-B Respiratory Symptoms Score at Day 28 [Time Frame: Baseline to Day 28] [Designated as safety issue: No]

The mean (SD) change in the Respiratory Symptoms score on the Quality of Life Questionnaire-Bronchiectasis (QOL-B) was measured from baseline to the end of Course 1 (Day 28). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.

Secondary Outcome Measures:

- Change in QOL-B Respiratory Symptoms Score at Day 84 [Time Frame: Baseline to Day 84] [Designated as safety issue: No]
  The mean (SD) change in the Respiratory Symptoms score on the QOL-B was measured from baseline to the end of Course 2 (Day 84). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.
- Time to Protocol-Defined Exacerbation (PDE) [Time Frame: Baseline to Day 112] [Designated as safety issue: No]
  Protocol-defined exacerbation was defined as an acute worsening of respiratory disease that triggered the initiation of a non-study antibiotic meeting at least 3 major criteria, or 2 major and at least 2 minor criteria. - Major Criteria: increased sputum production; increased discoloration of sputum; increased dyspnea; increased cough - Minor Criteria: fever (> 38º C) measured during clinic visit; increased malaise or fatigue; forced expiratory volume in 1 second (FEV1) (L) or forced vital capacity (FVC) decreased > 10% from baseline; new or increased hemoptysis

Enrollment: 274
Study Start Date: April 2011
Primary Completion Date: April 2013
Study Completion Date: July 2013

Arms	Assigned Interventions
Experimental: AZLI-AZLI Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.	Drug: AZLI AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
Placebo Comparator: Placebo-AZLI Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.	Drug: AZLI AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily Drug: Placebo Placebo to match AZLI administered via nebulizer three times daily

Eligibility

Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

- Male/Female 18 years or older with non-CF bronchiectasis
- Chronic sputum production on most days
- Positive sputum culture for gram-negative organisms
- Must have met lung function requirements

Exclusion Criteria:

- History of CF
- Hospitalized within 14 days prior to joining the study
- Previous exposure to AZLI
- Pregnant, breastfeeding, or unwilling to follow contraceptive measures for the study
- Must have met liver and kidney function requirements
- Continuous oxygen use of greater than 2 liters per minute (supplemental oxygen with activity and at night was allowed)
- Treatment for nontuberculous mycobacteria infection or active mycobacterium tuberculosis infection within 1 year of enrollment
- Other serious medical conditions.

Contacts and Locations

Locations

United States, Alabama
Florence Research Associates
Florence, Alabama, United States, 35630
United States, Arizona
Clinical Trials Connection
Flagstaff, Arizona, United States, 86001
Phoenix Medical Group
Peoria, Arizona, United States, 85381
Pulmonary Associates
Phoenix, Arizona, United States, 85006
AZ Pulmonary Specialists, LTD
Scottsdale, Arizona, United States, 85258
United States, California
Pulmonary Consultants & Primary Care Physicians Medical Group, Inc.
Orange, California, United States, 92780
UC San Diego Medical Center
San Diego, California, United States, 92103
California Pacific Medical Center
San Francisco, California, United States, 94115
United States, District of Columbia
Georgetown University Hospital
Washington, District of Columbia, United States, 20007
United States, Florida
University of Florida
Jacksonville, Florida, United States, 32209
University of Miami Miller School of Medicine

Miami, Florida, United States, 33136
Central Florida Pulmonary Group
Orlando, Florida, United States, 32803
Sarasota Memorial Hospital - Clinical Research Center
Sarasota, Florida, United States, 34239
Pasadena Center for Medical Research
St. Petersburg, Florida, United States, 33707
Tampa General Hospital - New Lung Associates
Tampa, Florida, United States, 33606
Florida Premier Research Institute
Winter Park, Florida, United States, 32789
United States, Georgia
Southeastern Lung Care PC
Decatur, Georgia, United States, 30033
United States, Illinois
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
United States, Iowa
Loess Hills Clinical Research
Council Bluffs, Iowa, United States, 51503
United States, Kentucky
Kentuckiana Pulmonary Associates
Louisville, Kentucky, United States, 40202
United States, Maryland
Pulmonary & Critical Care Associates of Baltimore
Rosedale, Maryland, United States, 21237
United States, New Jersey
Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08903
Pulmonary & Allergy Associates, P.A.
Summit, New Jersey, United States, 07901
United States, New York
Jamaica Hospital Medical Center
Jamaica, New York, United States, 11418
Columbia University, NY Presbyterian Hospital
New York, New York, United States, 10032
United States, North Carolina
UNC Chapel Hill
Chapel Hill, North Carolina, United States, 27599
United States, Oregon
The Oregon Clinic P.C./ Pulmonary Division
Portland, Oregon, United States, 97220
United States, Pennsylvania
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States, 19104

United States, Texas
University of Texas Health Science Center at Tyler
Tyler, Texas, United States, 75708
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84132
United States, Washington
Pulmonary Consultants, PLLC
Tacoma, Washington, United States, 98405
United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792
Medical College of Wisconsin Froedtert Hospital
Milwaukee, Wisconsin, United States, 53226
Australia, New South Wales
Concord Hospital
Concord, New South Wales, Australia, 2139
St Vincent's Hospital
Darlinghurst, New South Wales, Australia, 2010
St George Hospital
Kogarah, New South Wales, Australia, 2217
Royal Perth Hospital
Perth, New South Wales, Australia, 6000
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Repatriation General Hospital
Daw Park, South Australia, Australia, 5041
Burnside War Memorial Hospital Pharmacy
Toorak Gardens, South Australia, Australia, 5065
Australia, Western Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia, 6009
Belgium
CUB Hôpital Erasme
Brussels, Belgium, 1070
Universitair Ziekenhuis Antwerpen
Edegem, Belgium, 2650
KUL UZ Gasthuisberg
Leuven, Belgium, 3000
Canada, British Columbia
Kelowna Respiratory Research and Allergy Clinic
Kelowna, British Columbia, Canada, V1W 1V3

The Lung Centre at Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 1M9
Canada, Ontario
St. Michael's Hospital
Toronto, Ontario, Canada, M5B 1W8
France
CHICAS - Centre Hospitalier Intercommunal des Alpes du sud, site de GAP
Gap, PACA, France, 05007 Cedex
Service Activite Ambulatoire Pole Cardiovasculaire Hopital Nord
Marseille, France, 13015
CHU de Montpellier-Hopital Arnaud de Villeneuve
Montpellier Cedex 05, France, 34295
Hôpital Pasteur, CHU de Nice
Nice, France, 6002
Hopital Haut-Leveque
Pessac, France, 33604
CHU Toulouse - Hôpital Larrey
Toulouse, France, 31054 cedex 9
Germany
Charite Campus Virchow-Klinikum
Berlin, Germany, 12200
Research Center for Medical Studies (RCMS)
Berlin-Charlottenburg (Westend), Germany, 14052
Universitätsklinikum Freiburg
Freiburg, Germany, 79106
University Hospital Giessen
Giessen, Germany, 35392
Medizinische Hochschule Hannover
Hannover, Germany, 30625
Universitätsklinikum des Saarlandes
Homburg, Germany, 66421
Universitätsklinikum Jena Clinic for Internal Medicine II
Jena, Germany, 07747
POIS Leipzig GbR
Leipzig, Germany, 04357
Univ.-Klinikum Leipzig, Innere Med.
Leipzig, Germany, 04103
Klinikum Innenstadt der LMU Munchen
Munich, Germany, 80336
Italy
S.Anna Hospital, University of Ferrara
Ferrara, Italy, 44121
UO Broncopneumologia IRCCS Fondazione Cà Granda Milano
Milan, Italy, 20122
University of Modena and Reggio Emilia

Modena, Italy, 41100
Azienda Universitaria Federico II
Naples, Italy, 80131
Università di Pisa - Ospedale Cisanello
Pisa, Italy, 56124
Ospendale Civile Maggiore Centro Regionale Fibrosi Cistica
Verona, Italy, 37124
Netherlands
Medisch Centrum Alkmaar
Alkmaar, Netherlands, 1815 JD
Erasmus MC
Rotterdam, Netherlands, 3015GD
Spain
Hospital Vall d´Hebrón
Barcelona, Spain, 08035
Hospital Clinic i Provincial
Barcelona, Spain, 08036
Hospital Universitario de Bellvitge
Barcelona, Spain, 08907
Hospital Josep Trueta
Girona, Spain, 17007
Hospital Universitario La Paz
Madrid, Spain, 28046
Hospital La Fe
Valencia, Spain, 46009
United Kingdom
Papworth Hospital NHS Trust
Cambridgeshire, United Kingdom, CB23 3RE
Royal Infirmary of Edinburgh
Edinburgh, United Kingdom, EH16 4SA
Royal Devon and Exeter Hospital, NHS Foundation Trust
Exeter, United Kingdom, EX5 5AN
Sir William Leech Centre for Lung Research, Freeman Hospital
Newcastle upon Tyne, United Kingdom, NE7 7DN
GBS RE Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom, 532 1DA
Torbay District General Hospital
Torquay, Devon, United Kingdom, TQ2 7AA
Royal Wolverhampton Hospitals NHS Trust
Wolverhampton, United Kingdom, WV10 0QP

Investigators

Principal Investigator:	Anne O'Donnell, MD	Georgetown University Hospital

More Information

Responsible Party:	Gilead Sciences
Study ID Numbers:	GS-US-219-0104
Health Authority:	United States: Food and Drug Administration United Kingdom: Medicines and Healthcare Products Regulatory Agency Spain: Spanish Agency of Medicines Netherlands: Medicines Evaluation Board (MEB) Italy: The Italian Medicines Agency Germany: Federal Institute for Drugs and Medical Devices France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Belgium: Federal Agency for Medicinal Products and Health Products

Study Results

Participant Flow

Recruitment Details	Subjects were enrolled in a total of 90 study sites in the North America, Europe, and Australia. The first participant was screened on 25 April 2011. The last participant observation was on 01 July 2013.
Pre-Assignment Details	404 participants were screened, 274 were randomized and comprise the Intent-to-Treat (ITT) Analysis Set. 272 randomized participants received at least one dose of study drug and comprise the Safety Analysis Set.

Reporting Groups

	Description
AZLI-AZLI	Participants were randomized to receive blinded Aztreonam for Inhalation Solution (AZLI) 75 mg three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 84 days.
Placebo-AZLI	Participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 84 days.

Double-Blind Phase

	AZLI-AZLI	Placebo-AZLI
Started	136	138

	AZLI-AZLI	Placebo-AZLI
Randomized and Treated	135	137
Completed	119	123
Not Completed	17	15
Randomized but not treated	1	1
Adverse Event	10	4
Withdrawal by Subject	5	6
Lost to Follow-up	0	1
Sponsor request	1	2
Physician Decision	0	1

Open-Label Phase

	AZLI-AZLI	Placebo-AZLI
Started	112 [1]	110 [2]
Completed	102	98
Not Completed	10	12
Adverse Event	4	6
Withdrawal by Subject	1	2
Physician Decision	5	4

[1] 7 participants in this group did not continue from the randomized to the open-label phase.
[2] 13 participants in this group did not continue from the randomized to the open-label phase.

Baseline Characteristics

Analysis Population Description
ITT Analysis Set

Reporting Groups

	Description
AZLI-AZLI	Participants were randomized to receive blinded AZLI 75 mg three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.

	Description
Placebo-AZLI	Participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.

Baseline Measures

	AZLI-AZLI	Placebo-AZLI	Total
Number of Participants	136	138	274
Age, Continuous [units: years] Mean (Standard Deviation)	63.3 (14.22)	62.7 (13.33)	63.0 (13.75)
Age, Categorical [units: participants]			
<=18 years	0	0	0
Between 18 and 65 years	53	66	119
>=65 years	83	72	155
Gender, Male/Female [units: participants]			
Female	89	101	190
Male	47	37	84
Ethnicity (NIH/OMB) [units: participants]			
Hispanic or Latino	5	7	12
Not Hispanic or Latino	122	112	234
Unknown or Not Reported	9	19	28
Race/Ethnicity, Customized [units: participants]			
White	119	128	247
American Indian or Alaska Native	1	1	2
Asian	1	0	1
Black or African Heritage	2	4	6
Other	2	1	3

	AZLI-AZLI	Placebo-AZLI	Total
Not permitted	11	4	15
Region of Enrollment [units: participants]			
France	11	3	14
United States	58	52	110
Canada	0	2	2
Spain	22	17	39
Belgium	5	6	11
Australia	3	2	5
Netherlands	5	12	17
Germany	16	21	37
United Kingdom	11	11	22
Italy	5	12	17
QOL-B Respiratory Symptom Score [1] [units: units on a scale] Mean (Standard Deviation)	56.2 (17.98)	57.4 (18.07)	56.8 (18.00)

[1] The Quality of Life Questionnaire-Bronchiectasis (QOL-B) overall score was scaled from 0-100 with higher scores representing better quality of life.

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Change in QOL-B Respiratory Symptoms Score at Day 28
Measure Description	The mean (SD) change in the Respiratory Symptoms score on the Quality of Life Questionnaire-Bronchiectasis (QOL-B) was measured from baseline to the end of Course 1 (Day 28). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.
Time Frame	Baseline to Day 28
Safety Issue?	No

Analysis Population Description

Participants in the ITT Analysis Set with scores at both baseline and Day 28 were analyzed.

Reporting Groups

	Description
AZLI-AZLI	Participants were randomized to receive blinded AZLI 75 mg three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.
Placebo-AZLI	Participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.

Measured Values

	AZLI-AZLI	Placebo-AZLI
Number of Participants Analyzed	128	132
Change in QOL-B Respiratory Symptoms Score at Day 28 [units: units on a scale] Mean (Standard Deviation)	8.2 (17.13)	3.2 (14.67)

Statistical Analysis 1 for Change in QOL-B Respiratory Symptoms Score at Day 28

Statistical Analysis Overview	Comparison Groups	AZLI-AZLI, Placebo-AZLI
	Comments	[Not specified]
	Non-Inferiority or Equivalence Analysis?	No
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	0.011
	Comments	P-value was based on T-test from mixed-effect model repeated measures (MMRM).
	Method	Other [MMRM]
	Comments	[Not specified]
Method of Estimation	Estimation Parameter	Other [Differences in least squares mean]
	Estimated Value	4.6
	Confidence Interval	(2-Sided) 95% 1.1 to 8.2

	Estimation Comments	[Not specified]

2. Secondary Outcome Measure:

Measure Title	Change in QOL-B Respiratory Symptoms Score at Day 84
Measure Description	The mean (SD) change in the Respiratory Symptoms score on the QOL-B was measured from baseline to the end of Course 2 (Day 84). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.
Time Frame	Baseline to Day 84
Safety Issue?	No

Analysis Population Description

Participants in the ITT Analysis Set with scores at both baseline and Day 84 were analyzed.

Reporting Groups

	Description
AZLI-AZLI	Participants were randomized to receive blinded AZLI 75 mg three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.
Placebo-AZLI	Participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.

Measured Values

	AZLI-AZLI	Placebo-AZLI
Number of Participants Analyzed	123	125
Change in QOL-B Respiratory Symptoms Score at Day 84 [units: units on a scale] Mean (Standard Deviation)	5.6 (16.44)	3.9 (17.73)

Statistical Analysis 1 for Change in QOL-B Respiratory Symptoms Score at Day 84

Statistical Analysis Overview	Comparison Groups	AZLI-AZLI, Placebo-AZLI
	Comments	[Not specified]
	Non-Inferiority or Equivalence Analysis?	No

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.56
	Comments	P-value was based on T-test from mixed-effect model repeated measures (MMRM).
	Method	Other [MMRM]
	Comments	[Not specified]

Method of Estimation	Estimation Parameter	Other [Difference in least squares mean]
	Estimated Value	1.1
	Confidence Interval	(2-Sided) 95% -2.7 to 5.0
	Estimation Comments	[Not specified]

3. Secondary Outcome Measure:

Measure Title	Time to Protocol-Defined Exacerbation (PDE)
Measure Description	Protocol-defined exacerbation was defined as an acute worsening of respiratory disease that triggered the initiation of a non-study antibiotic meeting at least 3 major criteria, or 2 major and at least 2 minor criteria. • Major Criteria: increased sputum production; increased discoloration of sputum; increased dyspnea; increased cough • Minor Criteria: fever (> 38º C) measured during clinic visit; increased malaise or fatigue; forced expiratory volume in 1 second (FEV1) (L) or forced vital capacity (FVC) decreased > 10% from baseline; new or increased hemoptysis
Time Frame	Baseline to Day 112
Safety Issue?	No

Analysis Population Description
ITT Analysis Set

Reporting Groups

	Description
AZLI-AZLI	Participants were randomized to receive blinded AZLI 75 mg three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.

	Description
Placebo-AZLI	Participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.

Measured Values

	AZLI-AZLI	Placebo-AZLI
Number of Participants Analyzed	136	138
Time to Protocol-Defined Exacerbation (PDE) [units: days] Median (95% Confidence Interval)	NA (NA to NA) [1]	NA (NA to NA) [1]

[1] At least 50% of participants must have had a PDE in order to compute the median days to PDE. Fewer than 50% of participants in this group had a PDE, so median days to PDE could not be computed.

Reported Adverse Events

Time Frame	Baseline up to 30 days after the last dose of study drug
Additional Description	[Not specified]

Reporting Groups

	Description
AZLI-AZLI (Double-Blind)	Adverse events for this reporting group were reported from baseline to Day 112 while participants were receiving double-blind AZLI; participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.
Placebo-AZLI (Double-Blind)	Adverse events for this reporting group were reported from baseline to Day 112 while participants were receiving double-blind placebo; participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.

	Description
AZLI-AZLI (Open-Label)	Adverse events for this reporting group were reported from Day 112 to Day 196 plus 30 days while participants were receiving open-label AZLI; participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.
Placebo-AZLI (Open-Label)	Adverse events for this reporting group were reported from Day 112 to Day 196 plus 30 days while participants were receiving open-label AZLI; participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.

Serious Adverse Events

	AZLI-AZLI (Double-Blind)	Placebo-AZLI (Double-Blind)	AZLI-AZLI (Open-Label)	Placebo-AZLI (Open-Label)
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	18/135 (13.33%)	16/137 (11.68%)	8/112 (7.14%)	9/110 (8.18%)
Cardiac disorders				
Atrial fibrillation [A] †	1/135 (0.74%)	0/137 (0%)	1/112 (0.89%)	0/110 (0%)
Cardiac failure [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)
Endocrine disorders				
Hyperthyroidism [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)
Gastrointestinal disorders				
Abdominal pain upper [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)
Gastrointestinal haemorrhage [A] †	0/135 (0%)	0/137 (0%)	0/112 (0%)	1/110 (0.91%)
Intestinal obstruction [A] †	0/135 (0%)	1/137 (0.73%)	0/112 (0%)	0/110 (0%)
General disorders				
Device malfunction [A] †	0/135 (0%)	0/137 (0%)	1/112 (0.89%)	0/110 (0%)
Infections and infestations				
Bronchitis [A] †	2/135 (1.48%)	0/137 (0%)	0/112 (0%)	0/110 (0%)
Diverticulitis [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)

	AZLI-AZLI (Double-Blind)	Placebo-AZLI (Double-Blind)	AZLI-AZLI (Open-Label)	Placebo-AZLI (Open-Label)
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Fungal oesophagitis [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)
Gastroenteritis [A] †	0/135 (0%)	0/137 (0%)	1/112 (0.89%)	0/110 (0%)
Infective exacerbation of bronchiectasis [A] †	4/135 (2.96%)	2/137 (1.46%)	0/112 (0%)	3/110 (2.73%)
Lung infection [A] †	0/135 (0%)	0/137 (0%)	1/112 (0.89%)	0/110 (0%)
Lung infection pseudomonal [A] †	0/135 (0%)	1/137 (0.73%)	0/112 (0%)	0/110 (0%)
Mycobacterium avium complex infection [A] †	0/135 (0%)	1/137 (0.73%)	0/112 (0%)	0/110 (0%)
Pneumonia [A] †	3/135 (2.22%)	2/137 (1.46%)	1/112 (0.89%)	1/110 (0.91%)
Sinusitis [A] †	0/135 (0%)	1/137 (0.73%)	0/112 (0%)	0/110 (0%)
Injury, poisoning and procedural complications				
Ankle fracture [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)
Fall [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)
Femur fracture [A] †	0/135 (0%)	0/137 (0%)	1/112 (0.89%)	0/110 (0%)
Foot fracture [A] †	0/135 (0%)	0/137 (0%)	0/112 (0%)	1/110 (0.91%)
Hip fracture [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)
Patella fracture [A] †	0/135 (0%)	1/137 (0.73%)	0/112 (0%)	0/110 (0%)
Wrist fracture [A] †	0/135 (0%)	1/137 (0.73%)	1/112 (0.89%)	0/110 (0%)
Metabolism and nutrition disorders				
Hypoglycaemia [A] †	0/135 (0%)	0/137 (0%)	0/112 (0%)	1/110 (0.91%)
Musculoskeletal and connective tissue disorders				
Arthralgia [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)
Lumbar spinal stenosis [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)
Osteoarthritis [A] †	0/135 (0%)	1/137 (0.73%)	0/112 (0%)	0/110 (0%)

	AZLI-AZLI (Double-Blind)	Placebo-AZLI (Double-Blind)	AZLI-AZLI (Open-Label)	Placebo-AZLI (Open-Label)
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Osteonecrosis [A] †	0/135 (0%)	0/137 (0%)	0/112 (0%)	1/110 (0.91%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)				
Basal cell carcinoma [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)
Breast neoplasm [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)
Oesophageal adenocarcinoma [A] †	0/135 (0%)	0/137 (0%)	1/112 (0.89%)	0/110 (0%)
Psychiatric disorders				
Depression [A] †	0/135 (0%)	0/137 (0%)	0/112 (0%)	1/110 (0.91%)
Renal and urinary disorders				
Renal failure acute [A] †	0/135 (0%)	0/137 (0%)	1/112 (0.89%)	1/110 (0.91%)
Respiratory, thoracic and mediastinal disorders				
Asthma [A] †	1/135 (0.74%)	1/137 (0.73%)	0/112 (0%)	0/110 (0%)
Chronic obstructive pulmonary disease [A] †	2/135 (1.48%)	6/137 (4.38%)	0/112 (0%)	0/110 (0%)
Dyspnoea [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	2/110 (1.82%)
Haemoptysis [A] †	0/135 (0%)	1/137 (0.73%)	0/112 (0%)	0/110 (0%)
Lung disorder [A] †	1/135 (0.74%)	1/137 (0.73%)	0/112 (0%)	0/110 (0%)
Lung infiltration [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)
Respiratory failure [A] †	0/135 (0%)	0/137 (0%)	2/112 (1.79%)	0/110 (0%)
Skin and subcutaneous tissue disorders				
Skin lesion [A] †	0/135 (0%)	1/137 (0.73%)	0/112 (0%)	0/110 (0%)
Vascular disorders				
Hypertensive crisis [A] †	1/135 (0.74%)	0/137 (0%)	0/112 (0%)	0/110 (0%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 15.1

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	AZLI-AZLI (Double-Blind)	Placebo-AZLI (Double-Blind)	AZLI-AZLI (Open-Label)	Placebo-AZLI (Open-Label)
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	112/135 (82.96%)	101/137 (73.72%)	54/112 (48.21%)	58/110 (52.73%)
Gastrointestinal disorders				
Diarrhoea [A] †	6/135 (4.44%)	8/137 (5.84%)	0/112 (0%)	0/110 (0%)
Nausea [A] †	7/135 (5.19%)	5/137 (3.65%)	0/112 (0%)	0/110 (0%)
General disorders				
Chills [A] †	10/135 (7.41%)	3/137 (2.19%)	0/112 (0%)	0/110 (0%)
Fatigue [A] †	25/135 (18.52%)	25/137 (18.25%)	14/112 (12.5%)	16/110 (14.55%)
Malaise [A] †	14/135 (10.37%)	19/137 (13.87%)	4/112 (3.57%)	6/110 (5.45%)
Non-cardiac chest pain [A] †	9/135 (6.67%)	13/137 (9.49%)	5/112 (4.46%)	10/110 (9.09%)
Pain [A] †	0/135 (0%)	0/137 (0%)	7/112 (6.25%)	3/110 (2.73%)
Pyrexia [A] †	30/135 (22.22%)	21/137 (15.33%)	12/112 (10.71%)	16/110 (14.55%)
Infections and infestations				
Rhinitis [A] †	2/135 (1.48%)	7/137 (5.11%)	0/112 (0%)	0/110 (0%)
Musculoskeletal and connective tissue disorders				
Arthralgia [A] †	6/135 (4.44%)	10/137 (7.3%)	0/112 (0%)	0/110 (0%)
Nervous system disorders				
Headache [A] †	17/135 (12.59%)	14/137 (10.22%)	7/112 (6.25%)	11/110 (10%)
Psychiatric disorders				
Insomnia [A] †	1/135 (0.74%)	7/137 (5.11%)	0/112 (0%)	0/110 (0%)
Respiratory, thoracic and mediastinal disorders				
Cough [A] †	66/135 (48.89%)	65/137 (47.45%)	27/112 (24.11%)	38/110 (34.55%)

	AZLI-AZLI (Double-Blind)	Placebo-AZLI (Double-Blind)	AZLI-AZLI (Open-Label)	Placebo-AZLI (Open-Label)
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Dyspnoea [A] †	50/135 (37.04%)	47/137 (34.31%)	26/112 (23.21%)	28/110 (25.45%)
Haemoptysis [A] †	12/135 (8.89%)	11/137 (8.03%)	0/112 (0%)	0/110 (0%)
Oropharyngeal pain [A] †	12/135 (8.89%)	14/137 (10.22%)	0/112 (0%)	0/110 (0%)
Productive cough [A] †	7/135 (5.19%)	4/137 (2.92%)	0/112 (0%)	0/110 (0%)
Sputum discoloured [A] †	48/135 (35.56%)	38/137 (27.74%)	21/112 (18.75%)	18/110 (16.36%)
Sputum increased [A] †	59/135 (43.7%)	50/137 (36.5%)	19/112 (16.96%)	23/110 (20.91%)
Throat irritation [A] †	7/135 (5.19%)	4/137 (2.92%)	0/112 (0%)	0/110 (0%)
Wheezing [A] †	18/135 (13.33%)	13/137 (9.49%)	11/112 (9.82%)	7/110 (6.36%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 15.1

Limitations and Caveats

[Not specified]

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:

- The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
- The study has been completed at all study sites for at least 2 years

Results Point of Contact:

Name/Official Title: Clinical Trial Disclosures
Organization: Gilead Sciences, Inc.

Phone:
Email: ClinicalTrialDisclosures@gilead.com